J&J-backed startup Rapport files for US IPO
Adds details on use of IPO proceeds in paragraph 5, background on epilepsy in paragraphs 6-7 and funding in paragraph 11
May 17 (Reuters) -Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson JNJ.N, filed for an initial public offering in the United States on Friday.
Rapport, which develops small molecule medicines for patients suffering from central nervous system disorders, is gearing up for a listing as the IPO market recovers from a slump amid increasing hopes of a soft landing for the economy.
The company said it will be selling shares in the IPO, but did not disclose how many nor the price range.
Rapport's net loss widened to $34.8 million in 2023 from $10.7 million a year earlier.
Initially named Precision Neuroscience NewCo, the company plans to use a portion of the IPO proceeds to advance the clinical development of its lead product candidate, RAP-219, for the treatment of focal epilepsy.
Epilepsy is one of the most common neurological diseases, affecting about 50 million people worldwide, according to the World Health Organization.
About 3 million adults in the United States suffer from epilepsy, with 60% of them or 1.8 million people having focal epilepsy.
The company's investors include biotech investor ARCH Venture, investment manager Cormorant Asset Management, fund manager Fidelity and healthcare venture firm Third Rock Ventures, among others.
Boston, Massachusetts-based Rapport was formed in February 2022 with founding support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC.
Last year, the company raised $150 million in a Series B funding round led by Cormorant. The round also included investments from Goldman Sachs Asset Management among other firms.
Since its inception, Rapport has raised about $250 million in equity capital from life sciences investors.
Rapport plans to list on the Nasdaq under the symbol "RAPP".
Goldman Sachs, Jefferies, TD Cowen and Stifel are the underwriters for the offering.
Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
